CSE - LLP
VANCOUVER, June 21, 2017 /CNW/ -
Collaborative Research Agreement with UBC
LeenLife Pharma International Inc. (CSE: LLP) ("LeenLife" or the "Company") announces it has entered into a collaborative research agreement with the University of British Columbia to analyze some LeenLife products. The testing requires gas chromatography/mass spec analysis of the reaction mixtures and some analysis by liquid chromatography/mass spec for structural determination.
The Company has decided to set up manufacturing facilities in the Greater Vancouver area. After a careful analysis of costs and market confidence, it was determined that the first manufacturing center should be close to the core of Company operations.
The Company has granted stock options to directors, officers and consultants to purchase up to a total 3,400,000 common shares, exercisable at a price of $0.18 per share. The stock options are exercisable for three years until June 20, 2020. All of the above-mentioned options have been granted pursuant to the Company's Stock Option Plan which was approved by the Company's shareholders on June 8, 2017 at its Annual General Meeting.
Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including statements that address the Transaction and the meeting of shareholders and those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs and the ability to achieve goals.
SOURCE LeenLife Pharma International Inc.
For further information: Stan Lis, CEO, Tel: 604 764-0518, E-mail: [email protected]